浙江奥翔药业股份有限公司发布以集中竞价交易方式回购公司股份进展公告。回购方案首次披露于2025 年1月27日，实施期限为2025年1月24日至2026年1月23日，预计回购金额5000万元 - 10000万元，用于股 权激励和/或员工持股计划。截至2025年9月30日，公司累计回购股份5,201,200股，占总股本比例 0.63%，已支付总金额50,006,023.36元，实际回购价格区间为7.52元/股 - 11.39元/股。2025年9月未实施 股份回购。 ...

证券代码：603229 证券简称：奥翔药业 公告编号：2025-040 浙江奥翔药业股份有限公司 关于合作产品甲磺酸伊马替尼片 获得《药品注册证书》的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，浙江奥翔药业股份有限公司（以下简称"公司"）全资子公司浙江麒 正药业有限公司（以下简称"麒正药业"）收到国家药品监督管理局核准签发的 甲磺酸伊马替尼片《药品注册证书》（证书编号：2025S02736）。现就相关情况公 告如下： 一、药品的基本情况 药品名称：甲磺酸伊马替尼片 剂型：片剂 规格：0.1g（按 C₂₉H₃₁N₇O 计） 申请事项：药品注册（境内生产） 注册分类：化学药品 4 类 处方药/非处方药：处方药 药品批准文号：国药准字 H20255339 上市许可持有人：浙江麒正药业有限公司 生产企业：浙江麒正药业有限公司 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品 符合药品注册的有关要求，批准注册，发给药品注册证书。质量标准、说明书、 标签及生产工艺照所附执行。药品生产企业应当符合药品生产质 ...

Core Viewpoint - Aoxiang Pharmaceutical (603229.SH) announced that its wholly-owned subsidiary, Zhejiang Qizheng Pharmaceutical Co., Ltd., received the drug registration certificate for Imatinib Mesylate Tablets from the National Medical Products Administration, marking a significant milestone in the company's product portfolio [1]. Group 1: Product Approval - The drug registration certificate (Certificate No. 2025S02736) for Imatinib Mesylate Tablets has been officially issued [1]. - Imatinib Mesylate Tablets are the world's first targeted molecular therapy for cancer, specifically indicated for patients with chronic myeloid leukemia (CML) in acute or accelerated phases, or those who have failed alpha-interferon treatment [1]. - The drug is also indicated for patients with unresectable or metastatic gastrointestinal stromal tumors (GIST) [1]. Group 2: Mechanism of Action - The active ingredient, Imatinib, is a tyrosine kinase inhibitor that effectively inhibits the Philadelphia chromosome gene, preventing the phosphorylation reaction from being catalyzed and leading to the loss of chromosome function [1]. - This mechanism results in the suppression of abnormal white blood cell proliferation [1]. - Imatinib also binds to the active site of tyrosine kinase, blocking its activity [1].

Core Viewpoint - The announcement highlights that Aoxiang Pharmaceutical's subsidiary, Zhejiang Qizheng Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the drug registration certificate of Imatinib Mesylate Tablets, marking a significant milestone in cancer treatment [1]. Group 1: Company Developments - Aoxiang Pharmaceutical's subsidiary, Zhejiang Qizheng Pharmaceutical, has been granted a drug registration certificate for Imatinib Mesylate Tablets [1]. - Imatinib Mesylate is recognized as the world's first targeted molecular therapy for cancer, specifically for chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GIST) [1]. Group 2: Product Details - Imatinib Mesylate Tablets are intended for patients in the accelerated phase or blast crisis of CML, as well as those with GIST who cannot undergo surgical resection or have metastatic disease [1]. - The active ingredient, Imatinib, functions as a tyrosine kinase inhibitor, effectively suppressing the Philadelphia chromosome gene and preventing abnormal white blood cell proliferation [1].

Core Viewpoint - Aoxiang Pharmaceutical (603229) announced that its wholly-owned subsidiary, Qizheng Pharmaceutical, received the drug registration certificate for Imatinib Mesylate Tablets from the National Medical Products Administration, marking a significant milestone in its collaboration with STADA for the development and commercialization of this product [1] Group 1 - The drug Imatinib Mesylate Tablets is the world's first targeted molecular therapy for cancer, specifically used for treating patients with chronic myeloid leukemia (CML) in the blast phase, accelerated phase, or chronic phase after failure of alpha-interferon therapy [1] - It is also indicated for patients with unresectable or metastatic gastrointestinal stromal tumors (GIST) [1]

Core Viewpoint - The company, Aoxiang Pharmaceutical (603229.SH), announced that its wholly-owned subsidiary, Zhejiang Qizheng Pharmaceutical Co., Ltd., has received the drug registration certificate for Imatinib Mesylate Tablets from the National Medical Products Administration, marking a significant milestone in the oncology sector [1] Group 1: Product Information - Imatinib Mesylate Tablets are the world's first targeted molecular therapy for cancer, specifically indicated for patients with chronic myeloid leukemia (CML) in acute or accelerated phases, or those who have failed alpha-interferon treatment, as well as for patients with unresectable or metastatic gastrointestinal stromal tumors (GIST) [1] - The active ingredient, Imatinib, is a tyrosine kinase inhibitor that effectively suppresses the Philadelphia chromosome gene, preventing the phosphorylation reaction from being catalyzed and leading to the loss of chromosome function, thereby inhibiting abnormal white blood cell proliferation [1] - Imatinib also binds to the active site of tyrosine kinase, blocking its activity [1]

Core Viewpoint - Aoxiang Pharmaceutical (603229.SH) announced that its wholly-owned subsidiary, Zhejiang Qizheng Pharmaceutical Co., Ltd., received the drug registration certificate for Imatinib Mesylate Tablets from the National Medical Products Administration, marking a significant milestone in the company's product portfolio [1]. Group 1: Product Approval - The drug registration certificate (Certificate No.: 2025S02736) is for Imatinib Mesylate Tablets, which is the world's first targeted molecular therapy for cancer [1]. - Imatinib Mesylate is indicated for patients with chronic myeloid leukemia (CML) in the acute phase, accelerated phase, or chronic phase after failure of alpha-interferon treatment, as well as for patients with unresectable or metastatic gastrointestinal stromal tumors (GIST) [1]. Group 2: Mechanism of Action - The active ingredient, Imatinib, is a tyrosine kinase inhibitor that effectively inhibits the Philadelphia chromosome gene, preventing the phosphorylation reaction from being catalyzed and leading to the loss of chromosome function [1]. - This mechanism helps to suppress the abnormal proliferation of white blood cells and also binds to the active site of tyrosine kinase, blocking its activity [1].

Investment Rating - The report maintains an "Accumulate" rating for the industry [5] Core Insights - The pharmaceutical and biotechnology industry is expected to experience a turning point and growth resonance, with a focus on the resilience of the raw material drug sector amidst various macro and micro factors [7][10] - The industry is characterized by a significant number of listed companies, totaling 494, with a total market value of 77,409.20 billion and a circulating market value of 70,487.38 billion [2] Summary by Sections Industry Overview - The report analyzes 47 representative raw material drug companies, indicating that despite pressures on revenue, the profit margins are showing improvement, reflecting the industry's resilience [10] - The average revenue growth rate for the 47 companies in the first half of 2025 was -5.38%, while the average growth rate of non-recurring net profit was 14.43% [10][12] Financial Performance - Key companies such as Xinhecheng, Aoruite, Tianyu Co., Meinuohua, and others have achieved over 10% growth in revenue and non-recurring net profit [10] - The report highlights that the non-recurring net profit of Xinhecheng increased significantly by 70.50% year-on-year in the first half of 2025 [10] Market Trends - The report notes that the prices of major raw materials are currently at low levels, particularly for certain categories like sartans and heparins, with expectations for gradual price recovery as excess capacity is cleared [7][10] - The investment strategy for the second half of the year focuses on identifying companies that are at a turning point in their existing business while also exploring new growth opportunities [7][10] Company Recommendations - The report suggests focusing on companies such as Tianyu Co., Sitaly, Tonghe Pharmaceutical, Meinuohua, Xianju Pharmaceutical, and Puluo Pharmaceutical for potential investment opportunities [7][10]

Group 1 - The company announced a share repurchase plan on September 1, stating it will buy back 3,201,800 shares through centralized bidding, which represents 0.39% of the total share capital [2]

证券代码：603229 证券简称：奥翔药业 公告编号：2025-039 浙江奥翔药业股份有限公司 关于以集中竞价交易方式回购公司股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2025/1/27 | | --- | --- | | 回购方案实施期限 | 2025/1/24~2026/1/23 | | 预计回购金额 | 5,000万元~10,000万元 | | 回购用途 | □减少注册资本 √用于股权激励和/或员工持股计划 | | | □用于转换公司可转债 | | | □为维护公司价值及股东权益 | | 累计已回购股数 | 5,201,200股 | | 累计已回购股数占总股本比例 | 0.63% | | 累计已回购金额 | 50,006,023.36元 | | 实际回购价格区间 | 7.52元/股~11.39元/股 | 公司将严格按照《上市公司股份回购规则》《上海证券交易所上市公司自律监 管指引第 7 号——回购股份》等相关规定，在回购期限内根据市场情况择机做出 回购决 ...